AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (1.6 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?

Longfei Denga,, Ping Liangb,c( ), Hongjuan Cuia,d( )
Cancer Center, Medical Research Institute, Southwest University, Chongqing 400716, China
Department of Neurosurgery, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China
Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400716, China

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Gene therapy holds great promise for curing cancer by editing the deleterious genes of tumor cells, but the lack of vector systems for efficient delivery of genetic material into specific tumor sites in vivo has limited its full therapeutic potential in cancer gene therapy. Over the past two decades, increasing studies have shown that lentiviral vectors (LVs) modified with different glycoproteins from a donating virus, a process referred to as pseudotyping, have altered tropism and display cell-type specificity in transduction, leading to selective tumor cell killing. This feature of LVs together with their ability to enable high efficient gene delivery in dividing and non-dividing mammalian cells in vivo make them to be attractive tools in future cancer gene therapy. This review is intended to summarize the status quo of some typical pseudotypings of LVs and their applications in basic anti-cancer studies across many malignancies. The opportunities of translating pseudotyped LVs into clinic use in cancer therapy have also been discussed.

Keywords

Cancer therapyGene deliveryClinical translationLentiviral vectorPseudotype

References

1

Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573): 351–360.
Crossref Google Scholar
2

Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372): eaan4672.
Crossref Google Scholar
3

Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5): e3015.
Crossref Google Scholar
4

Goswami R, Subramanian G, Silayeva L, et al. Gene therapy leaves a vicious cycle. Front Oncol. 2019;9: 297.
Crossref Google Scholar
5

Poorebrahim M, Sadeghi S, Fakhr E, et al. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit Rev Clin Lab Sci. 2019;56(6): 393–419.
Crossref Google Scholar
6

Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomater Res. 2019;23: 8.
Crossref Google Scholar
7

Duvergé A, Negroni M. Pseudotyping lentiviral vectors: when the clothes make the virus. Viruses. 2020;12(11): 1311.
Crossref Google Scholar
8

Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175(4025): 949–955.
Crossref Google Scholar
9

High KA, Anguela XM. Adeno-associated viral vectors for the treatment of hemophilia. Hum Mol Genet. 2016;25(R1): R36–R41.
Crossref Google Scholar
10

Orkin S, Motulsky, A. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Curr Sci. 1996;71(9): 658–659.
Google Scholar
11
Vogt VM. Retroviral virions and genomes. In: Coffin JM, Hughes SH, Varmus HE, eds. Retroviruses. NY: Cold Spring Harbor; 1997.
12

Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995;270(5235):475–480.
Crossref Google Scholar
13

Kamimura K, Suda T, Zhang G, Liu D. Advances in gene delivery systems. Pharmaceut Med. 2011;25(5):293–306.
Crossref Google Scholar
14

Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27.
Crossref Google Scholar
15

Babaei M, Eshghi H, Abnous K, Rahimizadeh M, Ramezani M. Promising gene delivery system based on polyethylenimine-modified silica nanoparticles. Cancer Gene Ther. 2017;24(4):156–164.
Crossref Google Scholar
16

Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01–G06.
Crossref Google Scholar
17

Slivac I, Guay D, Mangion M, Champeil J, Gaillet B. Non-viral nucleic acid delivery methods. Expet Opin Biol Ther. 2017;17(1):105–118.
Crossref Google Scholar
18

Patil S, Gao YG, Lin X, et al. The development of functional non-viral vectors for gene delivery. Int J Mol Sci. 2019;20(21):5491.
Crossref Google Scholar
19

Mohammadinejad R, Dehshahri A, Sagar Madamsetty V, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Contr Release. 2020;325:249–275.
Crossref Google Scholar
20

Caffery B, Lee JS, Alexander-Bryant AA. Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies. Nanomaterials. 2019;9(1):105.
Crossref Google Scholar
21

Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Targeted Ther. 2021;6(1):53.
Crossref Google Scholar
22

Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24(6):687–696.
Crossref Google Scholar
23

Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529–1541.
Crossref Google Scholar
24

Joglekar AV, Sandoval S. Pseudotyped lentiviral vectors: one vector, many guises. Hum Gene Ther Methods. 2017;28(6):291–301.
Crossref Google Scholar
25

Naldini L, Blömer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 1996;93(21):11382–11388.
Crossref Google Scholar
26

Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263–267.
Crossref Google Scholar
27

Blömer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997;71(9):6641–6649.
Crossref Google Scholar
28

Marquez Loza LI, Yuen EC, McCray Jr PB. Lentiviral vectors for the treatment and prevention of cystic fibrosis lung disease. Genes 2019;10(3):218.
Crossref Google Scholar
29

Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A. 2006;103(46):17372–17377.
Crossref Google Scholar
30

Yahya EB, Alqadhi AM. Recent trends in cancer therapy: a review on the current state of gene delivery. Life Sci. 2021;269:119087.
Crossref Google Scholar
31

Kumar P, Woon-Khiong C. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr Gene Ther. 2011;11(2):144–153.
Crossref Google Scholar
32

Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J. 2012;443(3):603–618.
Crossref Google Scholar
33

Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312(5996):763–767.
Crossref Google Scholar
34

Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9(4):551–562.
Crossref Google Scholar
35

Verhoeyen E, Cosset FL. Engineering the surface glycoproteins of lentiviral vectors for targeted gene transfer. Cold Spring Harb Protoc. 2009;2009(8):pdb.top59.
Crossref Google Scholar
36

Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005;5(4):387–398.
Crossref Google Scholar
37

Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A. 1993;90(17):8033–8037.
Crossref Google Scholar
38

Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A. 2013;110(18):7306–7311.
Crossref Google Scholar
39

Dautzenberg IJC, Rabelink MJWE, Hoeben RC. The stability of envelope-pseudotyped lentiviral vectors. Gene Ther. 2021;28(1–2):89–104.
Crossref Google Scholar
40

Nikolic J, Belot L, Raux H, Legrand P, Gaudin Y, Albertini AA. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat Commun. 2018;9(1):1029.
Crossref Google Scholar
41

Cao W, Henry MD, Borrow P, et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science. 1998;282(5396):2079–2081.
Crossref Google Scholar
42

Kunz S, Sevilla N, McGavern DB, Campbell KP, Oldstone MB. Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol. 2001;155(2):301–310.
Crossref Google Scholar
43

Frecha C, Lévy C, Costa C, et al. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol. 2011;85(12):5975–5985.
Crossref Google Scholar
44

Navaratnarajah CK, Generous AR, Yousaf I, Cattaneo R. Receptor-mediated cell entry of paramyxoviruses: mechanisms, and consequences for tropism and pathogenesis. J Biol Chem. 2020;295(9):2771–2786.
Crossref Google Scholar
45

Ding Q, von Schaewen M, Ploss A. The impact of hepatitis C virus entry on viral tropism. Cell Host Microbe. 2014;16(5):562–568.
Crossref Google Scholar
46

Douam F, Lavillette D, Cosset FL. The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci. 2015;129:63–107.
Crossref Google Scholar
47

Zhu ZH, Chen SS, Huang AS. Phenotypic mixing between human immunodeficiency virus and vesicular stomatitis virus or herpes simplex virus. J Acquir Immune Defic Syndr (1988). 1990;3(3):215–219.
Google Scholar
48

Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol. 1996;70(4):2581–2585.
Crossref Google Scholar
49

Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A. 1996;93(26):15266–15271.
Crossref Google Scholar
50

Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–8471.
Crossref Google Scholar
51

Perletti G, Osti D, Marras E, Tettamanti G, de Eguileor M. Generation of VSV-G pseudotyped lentiviral particles in 293T cells. J Cell Mol Med. 2004;8(1):142–143.
Crossref Google Scholar
52

Chen YH, Pallant C, Sampson CJ, et al. Rapid lentiviral vector producer cell line generation using a single DNA construct. Mol Ther Methods Clin Dev. 2020;19:47–57.
Crossref Google Scholar
53

Farley DC, Iqball S, Smith JC, Miskin JE, Kingsman SM, Mitrophanous KA. Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors-in vitro and in vivo implications. J Gene Med. 2007;9(5):345–356.
Crossref Google Scholar
54

Izumida M, Togawa K, Hayashi H, Matsuyama T, Kubo Y. Production of vesicular stomatitis virus glycoprotein-pseudotyped lentiviral vector is enhanced by Ezrin silencing. Front Bioeng Biotechnol. 2020;8:368.
Crossref Google Scholar
55

Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol. 2015;16(6):546–553.
Crossref Google Scholar
56

DePolo NJ, Reed JD, Sheridan PL, et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther. 2000;2(3):218–222.
Crossref Google Scholar
57

Croyle MA, Callahan SM, Auricchio A, et al. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J Virol. 2004;78(2):912–921.
Crossref Google Scholar
58

Schauber-Plewa C, Simmons A, Tuerk MJ, Pacheco CD, Veres G. Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther. 2005;12(3):238–245.
Crossref Google Scholar
59

Hwang BY, Schaffer DV. Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. Gene Ther. 2013;20(8):807–815.
Crossref Google Scholar
60

Liang M, Yan M, Lu Y, Chen IS. Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell. Hum Gene Ther Methods. 2013;24(1):11–18.
Crossref Google Scholar
61

Pan D, Gunther R, Duan W, et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther. 2002;6(1):19–29.
Crossref Google Scholar
62

Pichlmair A, Diebold SS, Gschmeissner S, et al. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol. 2007;81(2):539–547.
Crossref Google Scholar
63

Baekelandt V, Eggermont K, Michiels M, Nuttin B, Debyser Z. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther. 2003;10(23):1933–1940.
Crossref Google Scholar
64

Velho TAF, Lovell PV, Friedrich SR, et al. Divergent low-density lipoprotein receptor (LDLR) linked to low VSV G-dependent viral infectivity and unique serum lipid profile in zebra finches. Proc Natl Acad Sci U S A. 2021;118(18):e2025167118.
Crossref Google Scholar
65

Chen Y, Ott CJ, Townsend K, Subbaiah P, Aiyar A, Miller WM. Cholesterol supplementation during production increases the infectivity of retroviral and lentiviral vectors pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G). Biochem Eng J. 2009;44(2–3):199–207.
Crossref Google Scholar
66

Skinner AM, Chakkaramakkil Verghese S, Kurre P. Cell-cell transmission of VSV-G pseudotyped lentivector particles. PLoS One. 2013;8(9):e74925.
Crossref Google Scholar
67

Zhang N, Huang H, Tan B, et al. Leucine-rich repeat-containing G protein-coupled receptor 4 facilitates vesicular stomatitis virus infection by binding vesicular stomatitis virus glycoprotein. J Biol Chem. 2017;292(40):16527–16538.
Crossref Google Scholar
68

Roesch F, OhAinle M, Emerman M. A CRISPR screen for factors regulating SAMHD1 degradation identifies IFITMs as potent inhibitors of lentiviral particle delivery. Retrovirology. 2018;15(1):26.
Crossref Google Scholar
69

Johnson LG, Olsen JC, Naldini L, Boucher RC. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther. 2000;7(7):568–574.
Crossref Google Scholar
70

Kremer KL, Dunning KR, Parsons DW, Anson DS. Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors. J Gene Med. 2007;9(5):362–368.
Crossref Google Scholar
71

Copreni E, Castellani S, Palmieri L, Penzo M, Conese M. Involvement of glycosaminoglycans in vesicular stomatitis virus G glycoprotein pseudotyped lentiviral vector-mediated gene transfer into airway epithelial cells. J Gene Med. 2008;10(12):1294–1302.
Crossref Google Scholar
72

Copreni E, Palmieri L, Castellani S, Conese M. A VSV-G pseudotyped last generation lentiviral vector mediates high level and persistent gene transfer in models of airway epithelium in vitro and in vivo. Viruses. 2010;2(8):1577–1588.
Crossref Google Scholar
73

Carpentieri C, Farrow N, Cmielewski P, et al. The effects of conditioning and lentiviral vector pseudotype on short- and long-term airway reporter gene expression in mice. Hum Gene Ther. 2021;32(15–16):817–827.
Crossref Google Scholar
74

Borok Z, Harboe-Schmidt JE, Brody SL, et al. Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. J Virol. 2001;75(23):11747–11754.
Crossref Google Scholar
75

Hanawa H, Kelly PF, Nathwani AC, et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther. 2002;5(3):242–251.
Crossref Google Scholar
76

Kim YS, Wielgosz MM, Hargrove P, et al. Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins. Mol Ther. 2010;18(7):1310–1317.
Crossref Google Scholar
77

Watson DJ, Kobinger GP, Passini MA, Wilson JM, Wolfe JH. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther. 2002;5(5 Pt 1):528–537.
Crossref Google Scholar
78

Wong LF, Azzouz M, Walmsley LE, et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther. 2004;9(1):101–111.
Crossref Google Scholar
79

Watson DJ, Passini MA, Wolfe JH. Transduction of the choroid plexus and ependyma in neonatal mouse brain by vesicular stomatitis virus glycoprotein-pseudotyped lentivirus and adeno-associated virus type 5 vectors. Hum Gene Ther. 2005;16(1):49–56.
Crossref Google Scholar
80

Schoderboeck L, Riad S, Bokor AM, et al. Chimeric rabies SADB19-VSVg-pseudotyped lentiviral vectors mediate long-range retrograde transduction from the mouse spinal cord. Gene Ther. 2015;22(5):357–364.
Crossref Google Scholar
81

MacKenzie TC, Kobinger GP, Kootstra NA, et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther. 2002;6(3):349–358.
Crossref Google Scholar
82

Kobinger GP, Deng S, Louboutin JP, et al. Transduction of human islets with pseudotyped lentiviral vectors. Hum Gene Ther. 2004;15(2):211–219.
Crossref Google Scholar
83

Hachiya A, Sriwiriyanont P, Patel A, et al. Gene transfer in human skin with different pseudotyped HIV-based vectors. Gene Ther. 2007;14(8):648–656.
Crossref Google Scholar
84

Matsumoto H, Kimura T, Haga K, Kasahara N, Anton P, McGowan I. Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors. BMC Gastroenterol. 2010;10:44.
Crossref Google Scholar
85

Petersen GF, Hilbert B, Trope G, Kalle W, Strappe P. Efficient transduction of equine adipose-derived mesenchymal stem cells by VSV-G pseudotyped lentiviral vectors. Res Vet Sci. 2014;97(3):616–622.
Crossref Google Scholar
86

Zhou X, Ramachandran S, Mann M, Popkin DL. Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. Viruses. 2012;4(11):2650–2669.
Crossref Google Scholar
87

Miletic H, Bruns M, Tsiakas K, et al. Retroviral vectors pseudotyped with lymphocytic choriomeningitis virus. J Virol. 1999;73(7):6114–6116.
Crossref Google Scholar
88

Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol. 2002;76(3):1488–1495.
Crossref Google Scholar
89

Park F. Correction of bleeding diathesis without liver toxicity using are naviral-pseudotyped HIV-1-based vectors in hemophilia A mice. Hum Gene Ther. 2003;14(15):1489–1494.
Crossref Google Scholar
90

Beyer WR, Pöpplau D, Garten W, von Laer D, Lenz O. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J Virol. 2003;77(5):2866–2872.
Crossref Google Scholar
91

Dylla DE, Xie L, Michele DE, Kunz S, McCray Jr PB. Altering alpha-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism. Genet Vaccine Ther. 2011;9:8.
Crossref Google Scholar
92

Zhang C, Hu B, Xiao L, Liu Y, Wang P. Pseudotyping lentiviral vectors with lymphocytic choriomeningitis virus glycoproteins for transduction of dendritic cells and in vivo immunization. Hum Gene Ther Methods. 2014;25(6):328–338.
Crossref Google Scholar
93

Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci. 2006;119(Pt 2):199–207.
Crossref Google Scholar
94

Miletic H, Fischer YH, Neumann H, et al. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Hum Gene Ther. 2004;15(11):1091–1100.
Crossref Google Scholar
95

Steffens S, Tebbets J, Kramm CM, Lindemann D, Flake A, Sena-Esteves M. Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. J Neuro Oncol. 2004;70(3):281–288.
Crossref Google Scholar
96

Muik A, Kneiske I, Werbizki M, et al. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol. 2011;85(11):5679–5684.
Crossref Google Scholar
97

Shimojima M, Kawaoka Y. Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus glycoprotein. J Vet Med Sci. 2012;74(10):1363–1366.
Crossref Google Scholar
98

Cannon JR, Sew T, Montero L, Burton EA, Greenamyre JT. Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol. 2011;228(1):41–52.
Crossref Google Scholar
99

Stein CS, Martins I, Davidson BL. The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. Mol Ther. 2005;11(3):382–389.
Crossref Google Scholar
100

Bester JC. Measles and measles vaccination: a review. JAMA Pediatr. 2016;170(12):1209–1215.
Crossref Google Scholar
101

Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893–897.
Crossref Google Scholar
102

Tatsuo H, Yanagi Y. The morbillivirus receptor SLAM (CD150). Microbiol Immunol. 2002;46(3):135–142.
Crossref Google Scholar
103

Amirache F, Lévy C, Costa C, et al. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood. 2014;123(9):1422–1424.
Crossref Google Scholar
104

Funke S, Schneider IC, Glaser S, et al. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther. 2009;16(5):700–705.
Crossref Google Scholar
105

Frecha C, Costa C, Nègre D, et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood. 2008;112(13):4843–4852.
Crossref Google Scholar
106

Frecha C, Costa C, Lévy C, et al. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood. 2009;114(15):3173–3180.
Crossref Google Scholar
107

Humbert JM, Frecha C, Amirache Bouafia F, et al. Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells. J Virol. 2012;86(9):5192–5203.
Crossref Google Scholar
108

Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75(2):295–305.
Crossref Google Scholar
109

Ozog S, Chen CX, Simpson E, et al. CD46 null packaging cell line improves measles lentiviral vector production and gene delivery to hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev. 2018;13:27–39.
Crossref Google Scholar
110

Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, Buchholz CJ. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One. 2012;7(10):e46667.
Crossref Google Scholar
111

Lévy C, Amirache F, Costa C, et al. Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells. Mol Ther. 2012;20(9):1699–1712.
Crossref Google Scholar
112

Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215–229.
Crossref Google Scholar
113

Douam F, Dao Thi VL, Maurin G, et al. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology. 2014;59(3):776–788.
Crossref Google Scholar
114

Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol. 2004;78(3):1448–1455.
Crossref Google Scholar
115

McKeating JA, Zhang LQ, Logvinoff C, et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol. 2004;78(16):8496–8505.
Crossref Google Scholar
116

Flint M, von Hahn T, Zhang J, et al. Diverse CD81 proteins support hepatitis C virus infection. J Virol. 2006;80(22):11331–11342.
Crossref Google Scholar
117

Lavillette D, Tarr AW, Voisset C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology. 2005;41(2):265–274.
Crossref Google Scholar
118

Pöhlmann S, Zhang J, Baribaud F, et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol. 2003;77(7):4070–4080.
Crossref Google Scholar
119

Lozach PY, Amara A, Bartosch B, et al. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem. 2004;279(31):32035–32045.
Crossref Google Scholar
120

Régeard M, Trotard M, Lepère C, Gripon P, Le Seyec J. Entry of pseudotyped hepatitis C virus into primary human hepatocytes depends on the scavenger class B type I receptor. J Viral Hepat. 2008;15(12):865–870.
Crossref Google Scholar
121

Bartosch B, Vitelli A, Granier C, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 2003;278(43):41624–41630.
Crossref Google Scholar
122

Harris HJ, Farquhar MJ, Mee CJ, et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol. 2008;82(10):5007–5020.
Crossref Google Scholar
123

Zeisel MB, Koutsoudakis G, Schnober EK, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology. 2007;46(6):1722–1731.
Crossref Google Scholar
124

Haid S, Windisch MP, Bartenschlager R, Pietschmann T. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol. 2010;84(2):964–975.
Crossref Google Scholar
125

Zheng A, Yuan F, Li Y, et al. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol. 2007;81(22):12465–12471.
Crossref Google Scholar
126

Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17(5):589–595.
Crossref Google Scholar
127

Wu X, Lee EM, Hammack C, et al. Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. J Virol. 2014;88(15):8433–8444.
Crossref Google Scholar
128

Yang W, Hood BL, Chadwick SL, et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology. 2008;48(5):1396–1403.
Crossref Google Scholar
129

Kim S, Ishida H, Yamane D, et al. Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. J Virol. 2013;87(8):4214–4224.
Crossref Google Scholar
130

Liang Y, Zhang G, Li Q, et al. TRIM26 is a critical host factor for HCV replication and contributes to host tropism. Sci Adv. 2021;7(2):eabd9732.
Crossref Google Scholar
131

Matsuura Y, Tani H, Suzuki K, et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology. 2001;286(2):263–275.
Crossref Google Scholar
132

Lagging LM, Meyer K, Owens RJ, Ray R. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol. 1998;72(5):3539–3546.
Crossref Google Scholar
133

Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197(5):633–642.
Crossref Google Scholar
134

Op De Beeck A, Voisset C, Bartosch B, et al. Characterization of functional hepatitis C virus envelope glycoproteins. J Virol. 2004;78(6):2994–3002.
Crossref Google Scholar
135

Deng Y, Guan J, Wen B, et al. Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles. PLoS One. 2013;8(4):e62684.
Crossref Google Scholar
136

Garrone P, Fluckiger AC, Mangeot PE, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med. 2011;3(94):94ra71.
Crossref Google Scholar
137

Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555.
Crossref Google Scholar
138

Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 1999;6(5):715–728.
Crossref Google Scholar
139

Gerolami R, Uch R, Jordier F, et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther. 2000;7(9):1286–1292.
Crossref Google Scholar
140

Diaz RM, Bateman A, Emiliusen L, et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther. 2000;7(19):1656–1663.
Crossref Google Scholar
141

Baldari S, Di Rocco G, Magenta A, Picozza M, Toietta G. Extracellular vesicles-encapsulated microRNA-125b produced in genetically modified mesenchymal stromal cells inhibits hepatocellular carcinoma cell proliferation. Cells. 2019;8(12):1560.
Crossref Google Scholar
142

Zhao P, Wang C, Fu Z, et al. Lentiviral vector mediated siRNA knock-down of hTERT results in diminished capacity in invasiveness and in vivo growth of human glioma cells in a telomere length-independent manner. Int J Oncol. 2007;31(2):361–368.
Crossref Google Scholar
143

Zorzan M, Del Vecchio C, Vogiatzis S, et al. Targeting the regulatory subunit R2Alpha of protein kinase A in human glioblastoma through shRNA-expressing lentiviral vectors. Viruses. 2021;13(7):1361.
Crossref Google Scholar
144

Saraga G, Mafficini A, Ghaneh P, Sorio C, Costello E. Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. Cancer Gene Ther. 2007;14(9):781–790.
Crossref Google Scholar
145

Chen C, Akerstrom V, Baus J, Lan MS, Breslin MB. Comparative analysis of the transduction efficiency of five adeno associated virus serotypes and VSV-G pseudotype lentiviral vector in lung cancer cells. Virol J. 2013;10:86.
Crossref Google Scholar
146

Ao Z, Chen W, Tan J, et al. Lentivirus-based virus-like particles mediate delivery of caspase 8 into breast cancer cells and inhibit tumor growth. Cancer Biother Radiopharm. 2019;34(1):33–41.
Crossref Google Scholar
147

Wang M, Li X, Xie W, et al. Inhibitory Effect of Lentivirus-Mediated Gag-Caspase-8 on the Growth of HER-2-Overexpressing Primary Human Breast Cancer Cells. Cancer Biother Radiopharm. 2021.
Crossref Google Scholar
148

Matsunaga W, Ichikawa M, Ishikawa T, Gotoh A. Lentiviral vector-mediated transfection of p53, p16 and PTEN genes against human renal cell carcinoma cell lines. Pers Med Universe. 2019;8:10–14.
Crossref Google Scholar
149

Shichinohe T, Bochner BH, Mizutani K, et al. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther. 2001;8(11):879–889.
Crossref Google Scholar
150

Bovia F, Salmon P, Matthes T, et al. Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors. Blood. 2003;101(5):1727–1733.
Crossref Google Scholar
151

Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood. 2005;105(6):2510–2518.
Crossref Google Scholar
152

Kock N, Kasmieh R, Weissleder R, Shah K. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia. 2007;9(5):435–442.
Crossref Google Scholar
153

Wang X, Liu P, Liu H, et al. Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma. Cancer Gene Ther. 2012;19(12):822–827.
Crossref Google Scholar
154

Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 2001;8(9):628–635.
Crossref Google Scholar
155

De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther. 2003;14(12):1193–1206.
Crossref Google Scholar
156

Simmons A, Whitehead RP, Kolokoltsov AA, Davey RA. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. Virol J. 2006;3:8.
Crossref Google Scholar
157

Yang S, Cohen CJ, Peng PD, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008;15(21):1411–1423.
Crossref Google Scholar
158

Bobisse S, Rondina M, Merlo A, et al. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 2009;69(24):9385–9394.
Crossref Google Scholar
159

Lo Presti V, Cornel AM, Plantinga M, et al. Efficient lentiviral transduction method to gene modify cord blood CD8(+) T cells for cancer therapy applications. Mol Ther Methods Clin Dev. 2021;21:357–368.
Crossref Google Scholar
160

Dullaers M, Van Meirvenne S, Heirman C, et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 2006;13(7):630–640.
Crossref Google Scholar
161

Miletic H, Fischer YH, Giroglou T, et al. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res. 2007;13(22 Pt 1):6761–6768.
Crossref Google Scholar
162

Miletic H, Huszthy P, Giroglou T, Bjerkvig R, von Laer D. 205. lentiviral pseudotyped vectors specifically and efficiently transduce invasive human glioblastoma xenografts. Mol Ther. 2008;16:S77–S78.
Crossref Google Scholar
163

Huszthy PC, Giroglou T, Tsinkalovsky O, et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One. 2009;4(7):e6314.
Crossref Google Scholar
164

He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol. 2005;174(6):3808–3817.
Crossref Google Scholar
165

Schoenhals M, Frecha C, Bruyer A, et al. Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins. Leukemia. 2012;26(7):1663–1670.
Crossref Google Scholar
166

Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011;62:249–264.
Crossref Google Scholar
167

Ou W, Marino MP, Suzuki A, et al. Specific targeting of human interleukin (IL)-13 receptor alpha2-positive cells with lentiviral vectors displaying IL-13. Hum Gene Ther Methods. 2012;23(2):137–147.
Crossref Google Scholar
168

Morgan RA, Gray D, Lomova A, Kohn DB. Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell. 2017;21(5):574–590.
Crossref Google Scholar
169

Lévy C, Amirache F, Girard-Gagnepain A, et al. Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent. Blood Adv. 2017;1(23):2088–2104.
Crossref Google Scholar
170

Andreou T, Rippaus N, Wronski K, et al. Hematopoietic stem cell gene therapy for brain metastases using myeloid cell-specific gene promoters. J Natl Cancer Inst. 2020;112(6):617–627.
Crossref Google Scholar
171

Zhou Q, Uhlig KM, Muth A, et al. Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors. J Immunol. 2015;195(5):2493–2501.
Crossref Google Scholar
172

Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J. Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors. Mol Ther Methods Clin Dev. 2019;13:371–379.
Crossref Google Scholar
173

Kravchenko YE, Frolova EI, Chumakov SP. Dual CAR-targeted natural killer cell lines demonstrate potent cytotoxic properties towards breast cancer cells. Int J Appl Exerc Physiol. 2020;9(12):13–19.
Google Scholar
174

Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462.
Crossref Google Scholar
175

Reghupaty SC, Sarkar D. Current status of gene therapy in hepatocellular carcinoma. Cancers. 2019;11(9):1265.
Crossref Google Scholar
176

Lee S, Kim YY, Ahn HJ. Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector. Biomaterials. 2021;272:120793.
Crossref Google Scholar
177

Brenner MK, Gottschalk S, Leen AM, Vera JF. Is cancer gene therapy an empty suit? Lancet Oncol. 2013;14(11):e447–e456.
Crossref Google Scholar
178

Ahani R, Roohvand F, Cohan RA, et al. Sindbis virus-pseudotyped lentiviral vectors carrying VEGFR2-specific nanobody for potential transductional targeting of tumor vasculature. Mol Biotechnol. 2016;58(11):738–747.
Crossref Google Scholar
179

Bryson PD, Han X, Truong N, Wang P. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. Vaccine. 2017;35(43):5842–5849.
Crossref Google Scholar
180

Kretschmer M, Kadlubowska P, Hoffmann D, Schwalbe B, Auerswald H, Schreiber M. Zikavirus pr ME envelope pseudotyped human immunodeficiency virus type-1 as a novel tool for glioblastoma-directed virotherapy. Cancers. 2020;12(4):1000.
Crossref Google Scholar
181

Argaw T, Marino MP, Timmons A, et al. In vivo targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand. Mol Ther Methods Clin Dev. 2021;21:670–680.
Crossref Google Scholar
182

Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17:63–89.
Crossref Google Scholar
183

Liang X, Liu L, Wei YQ, Gao GP, Wei XW. Clinical evaluations of toxicity and efficacy of nanoparticle-mediated gene therapy. Hum Gene Ther. 2018;29(11):1227–1234.
Crossref Google Scholar
184

De Lombaerde E, De Wever O, De Geest BG. Delivery routes matter: safety and efficacy of intratumoral immunotherapy. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188526.
Crossref Google Scholar
185

Mok W, Stylianopoulos T, Boucher Y, Jain RK. Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin Cancer Res. 2009;15(7):2352–2360.
Crossref Google Scholar
186

Smith E, Breznik J, Lichty BD. Strategies to enhance viral penetration of solid tumors. Hum Gene Ther. 2011;22(9):1053–1060.
Crossref Google Scholar
187

Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15(6):1955–1969.
Crossref Google Scholar
188

Kim YI, Ahn BC, Ronald JA, et al. Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model. J Vasc Intervent Radiol. 2012;23(5):704–711.
Crossref Google Scholar
189

Baliaka A, Zarogoulidis P, Domvri K, et al. Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53. Gene Ther. 2014;21(2):158–167.
Crossref Google Scholar
190

Smith SN, Schubert R, Simic B, et al. The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. Proc Natl Acad Sci U S A. 2021;118(21):e2017925118.
Crossref Google Scholar
191

Kasala D, Yoon AR, Hong J, Kim SW, Yun CO. Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy. Nanomedicine 2016;11(13):1689–1713.
Crossref Google Scholar
192

Zhang WW, Li L, Li D, et al. The first approved gene therapy product for cancer Ad-p53 (gendicine):12 years in the clinic. Hum Gene Ther. 2018;29(2):160–179.
Crossref Google Scholar
193

Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402–418.
Crossref Google Scholar
194

Kaikkonen MU, Räty JK, Airenne KJ, Wirth T, Heikura T, Ylä-Herttuala S. Truncated vesicular stomatitis virus G protein improves baculovirus transduction efficiency in vitro and in vivo. Gene Ther. 2006;13(4):304–312.
Crossref Google Scholar
195

Zhou S, Fatima S, Ma Z, et al. Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes. Mol Ther. 2016;24(6):1090–1099.
Crossref Google Scholar
196

Chen Y, Liu X, Zhang Y, et al. A self-restricted CRISPR system to reduce off-target effects. Mol Ther. 2016;24(9):1508–1510.
Crossref Google Scholar
197

Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268(5218):1766–1769.
Crossref Google Scholar
Genes & Diseases
Volume 10 Issue 5,
September 2023
Pages 1937-1955
DOI: 10.1016/j.gendis.2022.03.007
Cite this article:
Deng L, Liang P, Cui H. Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?. Genes & Diseases, 2023, 10(5): 1937-1955. https://doi.org/10.1016/j.gendis.2022.03.007

254

Views

4

Downloads

4

Crossref

6

Web of Science

5

Scopus

0

CSCD

Altmetrics
Received: 23 December 2021
Accepted: 03 March 2022
Published: 02 April 2022
© 2022 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return